Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK120 in Moderate-to-Severe Atopic Dermatitis (Ib/II)
CTR20212033Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of manfidokimab in atopic dermatitis (AD), sponsored by Akeso, Inc.. Started Aug 2021; status: completed.
02
Drugs
manfidokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20212033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212033.